Key statistics
As of last trade Fate Therapeutics Inc (F6T:FRA) traded at 1.18, -20.72% below its 52-week high of 1.49, set on Jun 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.18 |
|---|---|
| High | 1.18 |
| Low | 1.18 |
| Bid | 1.19 |
| Offer | 1.25 |
| Previous close | 1.27 |
| Average volume | 2.60k |
|---|---|
| Shares outstanding | 116.26m |
| Free float | 113.16m |
| P/E (TTM) | -- |
| Market cap | 172.07m USD |
| EPS (TTM) | -1.15 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 07:26 GMT.
More ▼
- Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
- Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
- Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
More ▼
